Header: A Yale pathology study presented at USCAP 2026 shows that NGS reimbursement denials are less about overuse and more about administrative failure—especially ICD-10 miscoding. Only 20% of cases were denied (275/1392), and most denials occurred despite guideline-concordant testing. The authors conclude, the fix is operational, not clinical.
Reimbursement Denials for NGS:
A Systems Problem, Not a Clinical One
[By Chat GPT 5.4]
At the March 2026 USCAP meeting, Korie et al. (Yale Pathology) presented a timely analysis of reimbursement denials for next-generation sequencing (NGS) in solid tumors:
Link (abstract PDF):
https://www.laboratoryinvestigation.org/action/showPdf?pii=S0023-6837%2825%2901936-1
The study evaluated 1,392 NGS tests performed between 2022–2023 at a large academic center. Of these, 275 cases (20%) were denied—a meaningful but not overwhelming fraction. That denominator matters: the system is not broadly failing, but the failures are highly patterned and correctable.
Key Findings
1. Denials cluster in common cancers and standard workflows
- Lung (30%), head & neck (11%), colorectal (8%)
- 80% ordered by treating physicians, not reflex testing
- Most cases were metastatic (47%) or initial diagnosis (31%)
This is not fringe utilization. These are core oncology use cases.
2. Guideline concordance is high—even among denials
- Lung: 88% met NCCN guidelines
- Colorectal: 91% met NCCN guidelines
This sharply undercuts any narrative that denials reflect inappropriate testing.
3. The dominant failure: ICD-10 coding errors
- 78% of denied cases involved incorrect ICD-10 codes
- Despite:
- 96% correct coding by ordering clinicians, and
- 100% correct coding in pathology reports
This suggests a breakdown in downstream billing workflows, not physician error.
4. Classic payer reasons still appear—but are secondary
- No prior authorization: 34%
- Not medically necessary: 25%
However, given the high NCCN concordance, these categories likely overlap with documentation or coding failures.
Interpretation
This is a textbook example of revenue cycle friction overwhelming clinical intent.
Three observations stand out:
First, the denial rate (20%) is real but not catastrophic. The system is functioning—but inefficiently.
Second, the disconnect between correct clinical documentation and incorrect billed ICD-10 codes is striking. This points to:
- Interface issues between EMR → LIS → billing systems
- Manual coding steps or mapping errors
- Possibly third-party billing workflows that degrade data fidelity
Third, payers are denying claims that—on retrospective review—clearly meet NCCN criteria. This creates a paradox:
The clinical system is aligned with guidelines; the reimbursement system is not aligned with the clinical system.
Operational Implications
For labs, pathology groups, and oncology programs:
1. Audit the ICD-10 transmission chain
- Where exactly does the correct code become incorrect?
- Is it:
- Order entry → LIS?
- LIS → billing export?
- Billing vendor transformation?
2. Treat coding as a “last-mile” quality metric
- Just as labs validate assays, they may need to validate coding integrity
- Random audits of denied vs paid claims can be highly informative
3. Reframe denial management
- These are not “medical necessity disputes” in the traditional sense
- They are often data integrity failures
4. Prior authorization remains relevant—but not dominant
- At 34%, it matters—but it is not the core story
Policy Angle
For those watching MolDx and broader Medicare/commercial alignment:
- The study reinforces that utilization management is not the central issue for NGS in common cancers
- Instead, administrative complexity creates artificial access barriers
This aligns with a broader pattern in precision oncology:
Coverage may exist on paper, but execution gaps determine real-world access.
Bottom Line
The Yale data suggest a simple but powerful conclusion:
NGS denials are often not about whether the test should be done—but whether the system can correctly describe what was done.
Fixing ICD-10 coding fidelity may yield more immediate reimbursement gains than any change in clinical policy or guideline alignment.
